Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

This trial (HI-MOC) is studying whether a combination of a second surgery to remove cancer (secondary cytoreductive surgery) plus heated chemotherapy washed directly into the abdomen (HIPEC) improves outcomes for people with recurrent mucinous ovarian cancer — a rare subtype of ovarian cancer that spreads along the lining of the abdomen and often behaves differently from the more common serous type. **You may be eligible if...** - You have been diagnosed with recurrent primary mucinous ovarian cancer, confirmed by biopsy or pathology - You are 18 or older with a performance status of ECOG 0–2 - Your blood counts and organ function (kidneys, liver) are adequate - You have recovered from any prior chemotherapy or radiation **You may NOT be eligible if...** - You are currently on another investigational treatment trial - Your mucinous tumor is confirmed to have come from another organ (e.g., appendix or colon) - You have active cancer spread to the brain - You have had severe reactions to HIPEC drugs (oxaliplatin or mitomycin-C) Talk to your doctor to see if this trial is right for you.